Glaukos Files PMA with US FDA for iStent Inject as Glaucoma Treatment

December 29, 2017: By Jon Swedien

Glaukos has submitted a premarket approval (PMA) application to the US FDA for the iStent Inject Trabecular Micro-Bypass Stent, the San Clemente, California, company announced Dec. 27.

The iStent Inject is designed to improve aqueous humor outflow into Schlemm’s canal and reduce intraocular pressure (IOP) in mild to moderate open-angle glaucoma patients undergoing cataract surgery, Glaukos said.

It includes two heparin-coated titanium stents preloaded in an auto-injection system that allows the surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point, the company said.

The iStent Inject met its primary effectiveness endpoint—a 20 percent or greater reduction in IOP from baseline at 24 months—in a prospective, randomized, multicenter clinical trial that included 41 sites and 505 randomized subjects, the company said. Glaukos said it plans to release efficacy and safety data from the trial in the first half of 2018.

The iStent Inject is currently approved for use in the European Union, Armenia, Australia, Brazil, Canada, Hong Kong, Singapore, and South Africa, Glaukos said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023